Purinergic receptor-mediated effects of adenosine 5′-triphosphate in urological malignant diseases: Review Article

International Journal of Urology

Volumn 16, Issue 2, 2009, Pages 143-150

  Shabbir, Majid ^a,b   Burnstock, Geoffrey ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Adenosine 5 triphosphate; Bladder; Cancer; Prostrate; Purinergic

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 4 (2 IODO 6 METHYLAMINO 9H PURIN 9 YL) 2 PHOSPHONOOXYBICYCLO[3.1.0]HEXANE 1 METHANOL; A 438079; A 740003; A 804598; ADENOSINE TRIPHOSPHATE DERIVATIVE; ANAZOLENE SODIUM; AR C 126313; AR C 67085; CALCIUM; HORMONE; MITOMYCIN; MITOXANTRONE; MRS 2279; MRS 2365; NF 157; NF 340; PSB 716; PURINERGIC P2 RECEPTOR; PURINERGIC P2X5 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y11 RECEPTOR; PURINERGIC P2Y2 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; RN 6189; SURAMIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CHEST TIGHTNESS; CLINICAL TRIAL; DIZZINESS; DYSPNEA; ERECTILE DYSFUNCTION; FLUSHING; GROWTH INHIBITION; HEADACHE; HEART PALPITATION; HUMAN; NAUSEA; NOCICEPTION; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SWEATING; URETER; URINARY TRACT; URINARY TRACT DISEASE;

ADENOSINE TRIPHOSPHATE; ANIMALS; CELL GROWTH PROCESSES; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, PURINERGIC; URINARY BLADDER NEOPLASMS;

EID: 60349123127     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02207.x     Document Type: Review

References (68)

1. Murphy GP, Slack NH. Response criteria for the prostate of the USA National Prostatic Cancer project. Prostate 1980 1 : 375 82.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J. Clin. 1999 49 : 8 31.
3. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol. Clin. North Am. 1993 20 : 303 21.
4. Kyprianou N, Martikainen P, Davis L, English HF, Isaacs JT. Programmed cell death as a new target for prostatic cancer therapy. Cancer Surv. 1991 11 : 265 77.
5. Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int. Rev. Cytol. 2004 240 : 31 304.
6. Burnstock G. Pathophysiology and therapeutic potential of purinergic signalling. Pharmacol. Rev. 2006 58 : 58 86.
7. Burnstock G. Purine-mediated signalling in pain and visceral perception. Trends. Pharmacol. Sci. 2001 22 : 182 8.
8. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. 2007 87 : 659 797.
9. Abbracchio MP, Burnstock G. Purinergic signalling: Pathophysiological roles. Jpn. J. Pharmacol. 1998 78 : 113 45.
10. Fang WG, Pirnia F, Bang YJ, Myers CE, Trepel JB. P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells. J. Clin. Invest. 1992 89 : 191 6.
11. Dury AN, Szent-Györgyi A. The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J. Physiol. (London) 1929 68 : 213 37.
12. Holton P. The liberation of adenosine triphosphate on antidromic stimulation of sensory nerves. J. Physiol. 1959 145 : 494 504.
13. Burnstock G, Campbell G, Satchell D, Smythe A. Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut. Br. J. Pharmacol. 1970 40 : 668 88.
14. Burnstock G, Dumsday B, Smythe A. Atropine resistant excitation of the urinary bladder: the possibility of transmission via nerves releasing a purine nucleotide. Br. J. Pharmacol. 1972 44 : 451 61.
15. Burnstock G. Do some nerve cells release more than one neurotransmitter? Neuroscience 1976 1 : 239 48.
16. Burnstock G. Neural nomenclature. Nature 1971 229 : 282 3.
17. Burnstock G. Purinergic nerves. Pharmacol. Rev. 1972 24 : 509 81.
18. Burnstock G. A basis for distinguishing two types of purinergic receptor. In : Straub RW, Bolis L (eds). Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. Raven Press, New York, 1978 107 18.
19. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 1998 50 : 413 92.
20. Burnstock G, Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen. Pharmacol. 1985 16 : 433 40.
21. Abbracchio MP, Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol. Ther. 1994 64 : 445 75.
22. North RA. Molecular physiology of P2X receptors. Physiol. Rev. 2002 82 : 1013 67.
23. Abbracchio MP, Burnstock G, Boeynaems JM et al. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 2006 58 : 281 341.
24. Burnstock G. Purine and pyrimidine receptors. Cell. Mol. Life Sci. 2007 64 : 1471 83.
25. Gregory S, Kern M. Adenosine and adenine nucleotides are mitogenic for mouse thymocytes. Biochem. Biophys. Res. Commun. 1978 83 : 1111 16.
26. Neary JT, Kang Y, Bu Y, Yu E, Akong K, Peters CM. Mitogenic signaling by ATP/P2Y purinergic receptors in astrocytes: involvement of a calcium-independent protein kinase C, extracellular signal-regulated protein kinase pathway distinct from the phosphatidylinositol-specific phospholipase C/calcium pathway. J. Neurosci. 1999 19 : 4211 20.
27. Nagelkerke JF, Dogterom P, De Bont HJ, Mulder GJ. Prolonged high intracellular free calcium concentrations induced by ATP are not immediately cytotoxic in isolated rat hepatocytes. Changes in biochemical parameters implicated in cell toxicity. Biochem. J. 263 : 347 53.
28. Murgia M, Pizzo P, Steinberg TH, Di Virgilio F. Characterization of the cytotoxic effect of extracellular ATP in J774 mouse macrophages. Biochem. J. 288 : 897 901.
29. 7 receptor of microglial cells: a novel immunomodulatory receptor. Prog. Brain Res. 1999 120 : 355 68.
30. Chiozzi P, Murgia M, Falzoni S, Ferrari D, Di Virgilio F. Role of the purinergic P2Z receptor in spontaneous cell death in J774 macrophage cultures. Biochem. Biophys. Res. Commun. 1996 218 : 176 81.
31. Di Virgilio F. Dr. Jekyll/Mr. Hyde: the dual role of extracellular ATP. J. Auton. Nerv. Syst. 2000 81 : 59 63.
32. 7 receptors by immunohistochemistry in rat stratified squamous epithelia. Cell Tissue Res. 1999 296 : 599 605.
33. 5 receptor on satellite cells. J. Cell Biol. 2002 158 : 345 55.
34. Rapaport E. Treatment of human tumor cells with ADP or ATP yields arrest of growth in the S phase of the cell cycle. J. Cell. Physiol. 1983 114 : 279 83.
35. Hopfner M, Lemmer K, Jansen A et al. Expression of functional P2-purinergic receptors in primary cultures of human colorectal carcinoma cells. Biochem. Biophys. Res. Commun. 1998 251 : 811 17.
36. Seetulsingh-Goorah SP, Stewart BW. Growth inhibition of HL-60 cells by extracellular ATP: concentration-dependent involvement of a P2 receptor and adenosine generation. Biochem. Biophys. Res. Commun. 1998 250 : 390 6.
37. 2Y2-receptors. Br. J. Cancer 2002 86 : 636 44.
38. Greig AVH, Linge C, Healy V et al. Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells. J. Invest. Dermatol. 2003 121 : 315 27.
39. Schafer R, Sedehizade F, Welte T, Reiser G. ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003 285 : L376 85.
40. 7 receptor-mediated apoptosis of human cervical epithelial cells. Am. J. Physiol. Cell Physiol. 2004 287 : C1349 58.
41. White N, Ryten M, Clayton E, Butler P, Burnstock G. P2Y purinergic receptors regulate the growth of human melanomas. Cancer Lett. 2005 224 : 81 91.
42. White N, Burnstock G. P2 receptors and cancer. Trends. Pharmacol. Sci. 2006 27 : 211 17.
43. Pizzo P, Murgia M, Zambon A et al. Role of P2z purinergic receptors in ATP-mediated killing of tumor necrosis factor (TNF)-sensitive and TNF-resistant L929 fibroblasts. J. Immunol. 1992 149 : 3372 8.
44. Zanovello P, Bronte V, Rosato A, Pizzo P, Di Virgilio F. Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. J. Immunol. 1990 145 : 1545 50.
45. 11 receptor in stably transfected haematological cell lines. Mol. Cell. Biochem. 2000 213 : 75 81.
46. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J. Clin. 2003 53 : 5 26.
47. Chun TY. Coincidence of bladder and prostate cancer. J. Urol. 1997 157 : 65 7.
48. Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of the European Organization for Research and Treatment of Cancer and the Medical Research Council randomized clinical trials for the prophylactic treatment of stage Ta, T1 bladder cancer. J. Urol. 1996 156 : 1934 41.
49. Jordan AM, Weingarten J, Murphy WM. Transitional cell neoplasms of the urinary bladder. Can biological potential be predicted from histologic grading? Cancer 1988 60 : 2766 74.
50. Janssens R, Boeynaems JM. Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells. Br. J. Pharmacol. 2001 132 : 536 46.
51. Shabbir M, Ryten M, Thompson C, Mikhailidis DP, Burnstock G. Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer. BJU Int. 2008 101 : 352 9.
52. 7 Receptor in human lymphocytes produces a delayed permeability lesion: involvement of phospholipase D. Arch. Biochem. Biophys. 2008 362 : 197 202.
53. 7 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J. Biol. Chem. 2006 281 : 2079 86.
54. 7 receptors. Histopathology 2004 44 : 206 15.
55. Kyprianou N, Isaacs JT. Thymineless' death in androgen-independent prostatic cancer cells. Biochem. Biophys. Res. Commun. 1989 165 : 73 81.
56. Martikainen P, Kyprianou N, Tucker RW, Isaacs JT. Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Res. 1991 51 : 4693 700.
57. Vanoverberghe K, Mariot P, Vanden Abeele F et al. P-induced calcium signaling and growth arrest in human prostate cancer cells. Cell Calcium. 2003 34 : 75 85.
58. Miyake H, Hara I, Yamanaka K, Arakawa S, Kamidono S. Calcium ionophore, ionomycin inhibits growth of human bladder cancer cells both in vitro and in vivo with alteration of Bcl-2 and Bax expression levels. J. Urol. 1999 162 : 916 21.
59. Shabbir M, Thompson C, Jarmulowiczc M, Mikhailidis DP, Burnstock G. Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo. BJU Int. 2008 102 : 108 12.
60. Boissier S, Magnetto S, Frappart L et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997 57 : 3890 4.
61. Mönkkönen H, Kuokkanen J, Holen I et al. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 2008 19 : 391 9.
62. 7 receptors to activate NF-κB in osteoclasts. J. Bone Miner. Res. 2004 19 : 642 51.
63. Shabbir M, Ryten M, Thompson C, Mikhailidis DP, Burnstock G. Purinergic receptor-mediated effects of ATP in high-grade bladder cancer. BJU Int. 2008 101 : 106 12.
64. Agteresch HJ, Dagnelie PC, Rietveld T, van den Berg JW, Danser AH, Wilson JH. Pharmacokinetics of intravenous ATP in cancer patients. Eur. J. Clin. Pharmacol. 2000 56 : 49 55.
65. Agteresch HJ, Dagnelie PC, van der Gaast A, Stijnen T, Wilson JH. Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer. J. Natl Cancer Inst. 2000 92 : 321 8.
66. Rapaport E, Fontaine J. Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools. Proc. Natl Acad. Sci. USA 1989 86 : 1662 6.
67. Agteresch HJ, Burgers SA, van der Gaast A, Wilson JH, Dagnelie PC. Randomized clinical trial of adenosine 5′-triphosphate on tumor growth and survival in advanced lung cancer patients. Anticancer Drugs 2003 14 : 639 44.
68. Arts IC, Swennen EL, Vandeurzen K, Dagnelie PC. Effect of ATP on survival, tumor response, nutritional status and quality of life in lung cancer patients: a multicentre, double-blind randomized trial. Purinergic Signal. 2008 4 : Sl 210.